Featured Research

from universities, journals, and other organizations

Even A Slight Elevation Of Cardiac Enzyme Predicts Mortality In Heart Patients

Date:
January 19, 2000
Source:
Duke University Medical Center
Summary:
New findings from an international clinical trial led by Duke University Medical Center show that a low-cost diagnostic test routinely taken on patients with a suspected heart attack is a more sensitive marker of heart damage than many physicians realize.

DURHAM, N.C. -- New findings from an international clinical trial led by Duke University Medical Center show that a low-cost diagnostic test routinely taken on patients with a suspected heart attack is a more sensitive marker of heart damage than many physicians realize.

Related Articles


A study published in the Jan. 19 issue of the Journal of the American Medical Association shows that even tiny increases in the test enzyme, known as creatine kinase-myocardial band, or CK-MB, can indicate injury to the heart and predict which patients with a suspected heart attack are at increased risk of death.

The enzyme is released into the bloodstream by dying heart muscle, and physicians have traditionally looked for substantial increases in CK-MB to help diagnose a heart attack. But this study is the first to definitively link even small levels of CK-MB elevation with increased risk of death and other negative outcomes, Duke researchers said.

"Physicians often ignore small increases in CK-MB, believing that only moderate to large increases signal a heart attack. But based on this study, physicians should pay attention to even the smallest increase," said the primary author of the study, Duke cardiologist Dr. John H. Alexander.

In addition to increased risk of death, patients with even slightly higher CK-MB levels also had higher rates of stroke, shock, congestive heart failure, ventricular arrhythmia, coronary procedures and bleeding complications, Alexander said. "The study also demonstrates that not all heart attacks are the same. The size of the heart attack matters and smaller is better."

The findings came from a double-blind, randomized, placebo-controlled trial of 9,461 patients at 726 hospitals in 28 countries. That study, known as PURSUIT (Platelet glycoprotein IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy), was designed to test the glycoprotein IIb/IIIa inhibitor eptifibatide (Integrilin), which is an intravenous "super aspirin."

Eptifibatide works by preventing platelets circulating in the blood from clumping together and forming a clot at the site of atherosclerotic plaque. Results of the trial, which was funded by Cor Therapeutics Inc. and published in 1998 in the New England Journal of Medicine, showed that treatment with eptifibatide was associated with reduced rates of death or heart attack by 30 days in these patients.

As part of the study, three CK-MB samples were collected from each patient at eight-hour intervals after enrollment into the trial. Researchers from the Duke Clinical Research Institute have now gone back and analyzed CK-MB data from these patients, along with their mortality rates at 30 days and six months after hospital admission, to determine the relationship between elevated CK-MB and risk of death.

They found that statistical analysis confirmed a strong relationship between CK-MB and mortality risk, even after adjustment for other baseline factors:

* In patients with normal peak CK-MB levels, the mortality rates were 1.8 percent and 4.0 perecnt at 30 days and six months, respectively.

* In patients with CK-MB elevated up to twice normal levels, those rates were 3.3 percent and 6.2 percent.

* For those with CK-MB levels 3 to 5 times normal, mortality rates were 5.1 percent and 7.5 percent.

* And for patients whose CK-MB was more than 10 times normal, mortality rates rose as high as 8.3 percent at 30 days and 11.0 percent at six months.

"This study extends the observations made in angioplasty trials that myocardial necrosis at even minimal levels above normal is important, raising the possibility that lowering the risk of myocardial necrosis through novel therapies could translate into a mortality benefit for patients," said Duke cardiologist Dr. Robert A. Harrington, senior author of the study.

Still, the authors caution that further study is needed. "The long-term clinical impact of reducing the size of infarctions still needs to be confirmed in other studies," Alexander said.


Story Source:

The above story is based on materials provided by Duke University Medical Center. Note: Materials may be edited for content and length.


Cite This Page:

Duke University Medical Center. "Even A Slight Elevation Of Cardiac Enzyme Predicts Mortality In Heart Patients." ScienceDaily. ScienceDaily, 19 January 2000. <www.sciencedaily.com/releases/2000/01/000119075845.htm>.
Duke University Medical Center. (2000, January 19). Even A Slight Elevation Of Cardiac Enzyme Predicts Mortality In Heart Patients. ScienceDaily. Retrieved November 28, 2014 from www.sciencedaily.com/releases/2000/01/000119075845.htm
Duke University Medical Center. "Even A Slight Elevation Of Cardiac Enzyme Predicts Mortality In Heart Patients." ScienceDaily. www.sciencedaily.com/releases/2000/01/000119075845.htm (accessed November 28, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Friday, November 28, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola Leaves Orphans Alone in Sierra Leone

Ebola Leaves Orphans Alone in Sierra Leone

AFP (Nov. 27, 2014) — The Ebola epidemic sweeping Sierra Leone is having a profound effect on the country's children, many of whom have been left without any family members to support them. Duration: 01:02 Video provided by AFP
Powered by NewsLook.com
Experimental Ebola Vaccine Shows Promise In Human Trial

Experimental Ebola Vaccine Shows Promise In Human Trial

Newsy (Nov. 27, 2014) — A recent test of a prototype Ebola vaccine generated an immune response to the disease in subjects. Video provided by Newsy
Powered by NewsLook.com
Pet Dogs to Be Used in Anti-Ageing Trial

Pet Dogs to Be Used in Anti-Ageing Trial

Reuters - Innovations Video Online (Nov. 26, 2014) — Researchers in the United States are preparing to discover whether a drug commonly used in human organ transplants can extend the lifespan and health quality of pet dogs. Video provided by Reuters
Powered by NewsLook.com
Today's Prostheses Are More Capable Than Ever

Today's Prostheses Are More Capable Than Ever

Newsy (Nov. 26, 2014) — Advances in prosthetics are making replacement body parts stronger and more lifelike than they’ve ever been. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins